NCT03054363 - Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

January 17, 2023

Study Completion Date

February 7, 2023

Conditions

Breast Cancer

Interventions

DRUG

Tucatinib in Combination with Palbociclib and Letrozole

"Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily"

DRUG

Tucatinib in Combination with Palbociclib and Letrozole

Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.

Trial Locations (6)

Stony Brook University, Stony Brook

Northwestern University, Chicago

University of Texas Health Science Center San Antonio, San Antonio

University of Colorado Denver, Aurora

University of Arizona, Tucson

New Mexico Cancer Care Alliance, Albuquerque